Fig. 1: ML-based model was developed based on clinical and non-clinical data of FDA-approved SMKIs to prospectively identify personalized kinase-specific safety signals. | Nature Communications

Fig. 1: ML-based model was developed based on clinical and non-clinical data of FDA-approved SMKIs to prospectively identify personalized kinase-specific safety signals.

From: Decoding kinase-adverse event associations for small molecule kinase inhibitors

Fig. 1

a Small molecule kinase inhibitors (SMKIs) approved by the U.S. FDA up to December 31, 2020. SMKIs were listed in the chronological order of their first FDA approval date with their generic names. Source data were retrieved from the FDA public website. b Characteristics of reporting odds ratio (ROR) profiles for combined top ten AEs of vandetanib, afatinib, erlotinib, and nintedanib. c The workflow of data integration and predictive modeling.

Back to article page